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Themicrotubule-associated protein tau is a principal component of neurofibril-
lary tangles, and has been identified as a key molecule in Alzheimer’s disease
and other tauopathies. However, it is unknown how a protein that is primarily
located in axons is involved in a disease that is believed to have a synaptic origin.
To investigate a possible synaptic function of tau, we studied synaptic plasticity
in the hippocampus and found a selective deficit in long-term depression (LTD)
in tau knockout mice in vivo and in vitro, an effect that was replicated by RNAi
knockdown of tau in vitro. We found that the induction of LTD is associated
with the glycogen synthase kinase-3-mediated phosphorylation of tau. These
observations demonstrate that tau has a critical physiological function in LTD.1. Introduction
The microtubule-associated protein ‘tau’ (MAPT) gene is located on chromosome
17 and consists of 16 exons [1]. Alternative splicing leads to six isoforms of tau, all
of which contain an amino-terminal projection domain and carboxy-terminalwith
microtubule-binding repeats [2]. Tau contains several critical serine and threonine
residues, the phosphorylation of which regulates its binding affinity for micro-
tubules [3,4]. It is believed that through this binding, tau has major roles in
stabilizing microtubules [5]. During neuronal development, tau expression is
increased in response to nerve growth factor [6], and subsequently enriched in
axons, a process that is required for maintaining axon morphology [7]. The
extent towhich taumay have additional functions unrelated to axonalmicrotubule
stabilization, however, is not known.
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ized by widespread accumulation of hyperphosphorylated
tau. Once hyperphosphorylated, tau is known to accumulate in
somatodendritic compartments and forms the core component
of neurofibrillary tangles (NFTs) [8]. It is generally believed that
hyperphosphorylation of tau is the critical step in causing it to
be missorted from the axon to dendrites, where it interferes
with neuronal function [9]. Associated with this accumula-
tion, there is a loss of synapses and eventually neurons [10,11].
However, the mechanism by which this occurs is unknown.
Increasing evidence suggests that in AD, synaptic dys-
function may initiate the cascades that result in cognitive
impairment and neurodegeneration. For example, it is well
established that oligomeric forms of b-amyloid (Ab) induce
a rapid alteration in synaptic plasticity, the process widely
believed to underlie learning and memory in the brain [12].
More specifically, Ab causes inhibition of long-term poten-
tiation (LTP) and enhancement of long-term depression
(LTD) in the hippocampus [13]. LTD involves the removal
of AMPA receptors (AMPARs) from synapses leading to a
reduction in synaptic efficiency, and can also result in the
shrinkage and elimination of synapses [14]. Therefore, a shift
in favour of LTDmay lead to neurodegeneration. That such pro-
cesses may be causally related to neurodegeneration in AD is
suggested by the finding that key molecules that are associated
with this disorder, such as glycogen synthase kinase (GSK)-3b
and caspase-3, are required for the induction of LTD in the hip-
pocampus [15–18] and mediate the Ab inhibition of LTP [19].
Interestingly, recent evidence has shown that Ab inhibition of
LTP is absent in the tau knockout (KO) mouse [20]. These
data, together with the observation that GSK-3b directly phos-
phorylates tau [15,18], suggest that tau may be a downstream
effector of GSK-3b in LTD. Therefore, we decided to examine
the role of tau in LTD in the hippocampus.
In this study, we found that in tau KO mice there is a loss
of LTD, whereas LTP is not affected. Furthermore, knock-
down of tau in hippocampal slices resulted in a complete
loss of LTD in the absence of any direct discernible effects
on synaptic transmission. We found that LTD was associated
with the phosphorylation of tau by GSK-3b [18]. Collectively,
these data suggest that tau phosphorylation is an essential
component of LTD.2. Results
(a) Long-term depression is absent in MAPTþ/ – and
MAPT – /– mice
The physiological role of tau in the hippocampus was initially
investigatedusing tauKOmice.We compared long-termsynap-
tic plasticity in adult (7–11 months old)MAPTþ/þ,MAPTþ/–
andMAPT –/– mice. Because the tau kinase GSK-3b is required
forLTD in thehippocampus [17], theprimary focusof our inves-
tigation was on this form of synaptic plasticity. Field excitatory
postsynaptic potentials (fEPSPs) were evoked in area CA1
of anaesthetized mice in response to electrical stimulation
of the ipsilateral Schaffer collateral–commissural pathway.
We found no differences in synaptic transmission between
MAPTþ/þ, MAPTþ/– and MAPT –/– mice, as assessed using
input–output curves (figure 1a), andweobservedno significant
differences in paired-pulse facilitation over a range of inter-
stimulus intervals (figure 1b). However, we found that whileLTD could be readily induced in adult MAPTþ/þ mice, it
was completely absent in MAPTþ/– and MAPT –/– mice
(figure 1c). By contrast, similar levels of LTP were observed in
the three genotypes (figure 1d). Therefore, tau is specifically
required for LTD in the hippocampus in vivo.
Next, we investigated LTD in acute brain slices from
young (14- to 17-day-old) mice. Consistent with the obser-
vations in vivo, LTD was absent in slices prepared from
MAPT2/2 mice but was readily induced in slices obtained
from MAPTþ/þ mice (figure 2a). We also investigated LTD
induced by a brief application of NMDA (25 mM, 3 min)
and found a specific deficit in slices from the MAPT –/–
mice (figure 2b). These results show that the LTD deficit
in MAPT –/– mice is apparent early in development and
therefore is not directly associated with ageing.
(b) Knockdown of tau by shRNA prevents long-term
depression induction
In these experiments, tau was absent or reduced throughout
the life of the animals, potentially leading to developmental
complications. Therefore, to investigate more directly whether
tau is involved in the LTD process, we used an shRNA probe
against rat tau and studied synaptic function in rat hippocam-
pal organotypic slice cultures (figure 3). To study the effects
of tau knockdown on synaptic transmission, simultaneous
recordings of excitatory postsynaptic currents (EPSCs) were
performed from tau-shRNA transfected and neighbouring
untransfected neurons. There were no significant differences
in AMPAR- and NMDA receptor (NMDAR)-mediated EPSCs
(EPSCA and EPSCN, respectively) between tau-shRNA trans-
fected cells and neighbouring untransfected neurons (EPSCA
in transfected cells, 252+12 pA; EPSCA in untransfected
cells, 253+18 pA, n ¼ 15 pairs, p. 0.05; EPSCN in transfected
cells, 256+16 pA; EPSCN in untransfected cells, 268+12 pA,
n ¼ 15 pairs, p. 0.05; figure 3a). We next investigatedwhether
tau-shRNA had any effect on LTD. Consistent with the LTD
experiments in MAPTþ/– and MAPT –/– mice, tau-shRNA
blocked LTD, whereas LTD was routinely induced in simul-
taneously recorded, neighbouring untransfected cells (tau-
shRNA transfected: 92+3% of baseline; untransfected: 63+
7%, n ¼ 5, p, 0.05, tau-shRNA versus control; figure 3b).
The blockof LTDwas a specific consequence of the knockdown
of endogenous tau, because expression of a non-effective,
scrambled tau-shRNA had no effect on LTD (61+7%, n ¼ 5,
p. 0.05, compared with control, figure 3c). Furthermore,
the tau-shRNA-mediated LTD deficit was rescued by co-
expression of human tau (60+4%, n ¼ 5, p. 0.05, compared
with control, figure 3d), which was resistant to knockdown
(rat tau-shRNA selectively reduces the expression of rat tau
but has no effect on human tau; data not shown). These find-
ings are consistent with our KO studies, confirming that tau
is required for LTD induction. Taken together, our data show
that tau is required for LTD across two species (rats and
mice) and in both juvenile and adult tissue.
(c) Tau is found in the postsynaptic compartment
The finding that tau is required for LTD is surprising since
LTD is generally considered to be mediated postsynaptically,
via the synaptic removal of AMPARs, whereas tau is present
primarily in axons. One possibility is that LTD causes the
redistribution of tau to dendritic shafts and/or spines. An
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mally expressed in a postsynaptic compartment and it is
specifically this fraction that is involved in LTD. We explored
the latter possibility in two ways. First, we used immunogold
electron microscopy (EM) and compared the labelling of
tissue from MAPTþ/þ and MAPT –/– mice (figure 4a). We
could detect some immunoreactivity within dendritic spines
of the MAPTþ/þ, but not MAPT –/– , mice. Second, we
probed for the presence of tau, and another microtubule-
associated protein (MAP2), in microsome/organelle (P3),
cytoplasmic (S3) and synaptosomal (LP1) fractions prepared
from the hippocampus of MAPTþ/þ mice (figure 4b). As
expected, tau and MAP2 were recovered in the P3 fraction
and to a lesser extent in the S3 fraction. However, tau was
additionally detected in the LP1 fraction. Thus, a proportion
of tau is localized at a postsynaptic site where it could, in
principle, function directly in LTD.
Because GSK-3b is a major tau kinase [15,18,21] and is
activated during LTD [17], this seemed a likely candidate to
mediate the physiological phosphorylation of tau. We hypoth-
esized that the GSK-3bmediated phosphorylation of tau could
be an important regulator of LTD. If this is indeed the case, then
a prediction is that the induction of LTD should be associated
with an increase in the phosphorylation of tau. To investigate
this, we delivered low-frequency stimulation (LFS) and
measured the phosphorylation status of tau in the CA1 micro-
dissected dendritic region of rat hippocampal slices (figure 4c).
We observed a dramatic increase in the phosphorylation of tauusing PHF-1 ( p, 0.01, n ¼ 4, figure 4d,e), an antibody that
recognizes phosphorylation at residues Ser396 and Ser404
[22], but observed no difference following LFS in the total
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phorylation-independent anti-tau antibody [23]. We next
tested whether the phosphorylation of tau was due to
activation of GSK-3 during LTD by applying a highly selec-
tive GSK-3b inhibitor, CT-99021, during LFS (figure 4d). This
treatment eliminated the increase in tau phosphorylation
(figure 4d,e), while having no effect on the total levels of
tau (assessed using Tau-5; figure 4d,f ). Collectively, these
data demonstrate that LFS leads to the phosphorylation of
tau in a GSK-3b-dependent manner, further supporting
the idea that this phosphorylation event has a key role in the
induction of LTD.3. Discussion
In this study, we have provided several lines of complementary
evidence to suggest that tau is important for LTD in thehippocampus. First, we have shown that LTD at CA1 synapses
in vivo is not detectable in mice in which tau is absent or its
expression levels are reduced. Second, we found that LTD
was absent in slices acutely prepared from juvenile hippocam-
pal tissues of MAPT2/2 mice. Third, we have demonstrated
that knockdown of tau completely blocks LTD in organoty-
pic-cultured slices. Fourth, we have shown that LFS used to
elicit physiological LTD leads to enhanced phosphorylation of
tau at the PHF-1 epitope, via a GSK-3b-dependent mechanism.
It iswidely believed that tau, undernormal conditions, is pri-
marily involved in stabilizing microtubules in axons, and that
the dysregulation of this function somehow leads to neuronal
pathology [24]. The most prevalent form of such dysregulation
occurs through the hyperphosphorylation of tau, which is
involved in the generation of NFTs and plays a key role in
neurodegenerative conditions such as AD [25]. Hyperpho-
sphorylated tau is missorted to somatodendrites instead of
axons,where it is known to accumulate [26–28]. Suchmissorting
is assumed to contribute to neuronal pathology, because it pos-
itions tau where it can interfere directly with synaptic function.
How tau becomes missorted is not known.
An alternative possibility is that some tau is normally
present at synapses and it is this tau that is specifically associ-
ated with the neuropathology. Indeed, emerging evidence
suggests that tau may be present in dendrites even in the
absence of tauopathy [29] and that it could regulate interactions
between scaffolding proteins and signalling pathways in the
postsynaptic density (PSD) [30]. Furthermore, the localization
of tau within the postsynaptic complex can be affected by
NMDAR activation [31]. This raises an important question as
to what the physiological function of tau in dendrites might
be. Here, we have found, using both tau KO mice and RNAi
in organotypic slices prepared from rats, that tau is required
for LTD. This role is likely to be specific, because we found
no evidence that tau is required for maintaining normal synap-
tic transmission or for LTP. Previous work [9,32] has shown
that overexpression of tau may lead to inhibition of LTP.
Based on the present findings, we propose that this may be
because excess activation of tau induces a chronic form of
LTD that is manifest as an impairment in LTP.
We also found that LFS, a physiological LTD induction
protocol, resulted in the phosphorylation of tau and that
this was dependent on GSK-3. Thus, tau is most probably a
physiological substrate of GSK-3b during LTD. The next
key question concerns the physiological downstream effec-
tors of tau during LTD. At present, we can only speculate
on this issue. Because tau is a microtuble-associated pro-
tein, and because microtubules may be involved in LTD
[33], it is possible that tau is involved in the regulation of
LTD-dependent microtubule dynamics.
Tau can be divided into a projection domain (towards the
N-terminus, encompassing an acidic region and a proline-
rich region) and a microtubule-binding domain (towards the
C-terminus, including the microtubule-binding repeat region)
[34], each having specific roles in the regulation of tau function
[35,36]. Within these domains exist multiple regulatory sites of
phosphorylation on serine/threonine residues. Our findings
suggest a role in LTD for serine residues within the PHF
epitope (Ser396/404). Consistent with our findings, Mondra-
gon-Rodriguez et al. [31] recently reported a facilitation of
Ser396/404 phosphorylation following NMDA treatment. Cri-
tically, Ser396/404 residues can both be phosphorylated by
GSK-3b [37,38], an enzyme that is required for the induction
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potential GSK-3b phosphorylation sites on tau are phosphory-
lated during the physiological activation of this kinase. Our
finding that phosphorylation of Ser396/404 following LFS is
prevented by CT-99021 demonstrates that GSK-3b is upstream
of tau in LTD and that this particular phosphorylation event
probably has a physiological function.4. Conclusion
We have shown that tau is required for NMDAR-dependent
LTD is the hippocampus. Our data suggest a model wherebyduring LTD, activation of GSK-3b leads to phosphorylation
of tau and this promotes LTD.5. Methods
(a) In vivo electrophysiology
MaleC57/BL6Jmicewereused forall comparativeKOexperiments.
MAPT2/2 and MAPTþ/2 mice were maintained by backcrossing
with C57/BL6J mice. Mice were individually housed and kept on
a 12 h light/dark schedule. All mice had free access to food and
water. Each mouse was anaesthetized with 3% isoflurane–air mix-
ture, and fixed in a stereotaxic device (model 900, David Kopf
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electrode (two enamel-coated wires with 10 mm diameter and
200 kV impedance) was positioned into stratum radiatum of the
left hippocampal CA1 area (21.7 mm from bregma, 1.65 mm from
medial, 1.3 mm depth) and a mono-polar recording electrode
(0.5–1 MV) was placed 200 mm posterior to the stimulating
electrode. The animal was maintained anaesthetized (1.5% isoflur-
ane–air mixture) for at least 3 h (body temperature was kept at
368C). For the fEPSPmeasurements, the electrical signal was ampli-
fied 100 times (ER-1, Cygnus Technology, USA), digitized (Digidata
1321A,Axon Instruments, FosterCity,CA,USA)andprocessedona
computer. To induce LTP, 100 pulses at 100 Hz were applied three
times (at 180 s intervals), and to induce LTD, 900 pulses at 1 Hz
were delivered. The amplitude and slope of each recorded fEPSP
wasmeasured by a custom application based onMATLAB (version
8,Mathworks Inc., CA, USA). fEPSPs were analysed only when the
maximal amplitudewasover 1 mV, and the latencyof theminimum
peak from stimulus was shorter than 7 ms. Experiments were
performed blindly.
(b) In vitro electrophysiology
For in vitro electrophysiology experiments, acute hippocampal
slices were obtained from P24 to P28 male Wistar rats or
MAPT2/2 and MAPTþ/2 mice. Animals were sacrificed by dis-
location of the neck and then decapitated. The brain was rapidly
removed and placed in ice-cold artificial cerebrospinal fluid
(aCSF) containing (in mM): NaCl 124, KCl 3, NaHCO3 26,
NaH2PO4 1.25, CaCl2 2, MgSO4 1 and D-glucose 10 (bubbled
with 95% O2/5% CO2). Transverse hippocampal slices (400 mm
thick) were prepared using a McIllwain tissue chopper (Mickle
Laboratory Engineering Co. Ltd., Gomshall, UK). Hippocampal
slices were stored in aCSF (20–258C) for 1–2 h before transfer-
ring to the recording chamber, in which they were submerged
in aCSF (308C) flowing at 2 ml min21. Extracellular field poten-
tials were recorded in the CA1 region using glass electrodes
containing NaCl (3 M). A stimulating electrode in CA2 was
used to evoke field EPSPs (constant voltage, 100 ms duration,
repeated at 30 s intervals). The slope of the evoked fEPSP was
measured and expressed relative to the normalized precondition-
ing baseline. Data were captured and analysed using WINLTP
(www.winltp.com). Experiments in which changes in the fibre
volley occurred were discarded.
(c) Hippocampal slice culture
Hippocampal slice cultures were prepared from 6- to 7-day-old
male Wistar rats, as previously described [19]. Whole-cell patch
clamp recordings of CA1 neurons transfected with shRNA plas-
mids were made 3–4 days following transfection. Using a
biolistic Gene Gun (BioRad, USA), neurons were transfected
with plasmids expressing shRNA against rat tau protein (OriGene
Technologies, MD, USA). A mixture of four different tau (0N/3R,
0N/4R, 1N/4R and 2N/4R) shRNA constructs (1 : 1 : 1 : 1, in
pGFP-V-RS vector) were used for tau silencing. A non-effective
scrambled sequence shRNAwas used as a negative control against
tau-shRNA. EPSCs were recorded using a multi-clamp 700B
amplifier (Axon Instruments). Recordingswere carried out in a sol-
ution containing (in mM): NaCl 119, KCl 2.5, CaCl2 4, MgCl2 4,
NaHCO3 26, NaH2PO4 1, glucose 11, picrotoxin 0.02 and 2-chlor-
oadenosine 0.01, gassed with 5% CO2/95% O2, at pH 7.4. To
induce LTD, 200 pulses at 1 Hz were delivered at a holding poten-
tial of 240 mV. AMPAR-mediated EPSC amplitude (EPSCA) was
determined as the peak EPSC amplitude at a holding potential
of 270 mV. NMDAR-mediated EPSC amplitude (EPSCN) was
determined 50–70 ms after the EPSCA peak at a holding potential
of þ40 mV. In some experiments, dual patch clamp recordings
were made simultaneously from a pair of neighbouring CA1 pyr-
amidal neurons, one transfected and the other untransfected.n values indicate number of cells, each obtained from independent
slices. Error bars indicate s.e.m.
(d) Tau constructs
0N3R and 2N4R human tau cDNAs were framed in pEGFP-C1
host vectors (Clontech, Mountain View, CA, USA), and provided
by Drs R. Brandt (University of Ostanbru¨ck, Germany) and
S. Lovestone (King’s College, UK).
(e) Immunogold electron microscopy
Under deep pentobarbital anaesthesia, animals were perfused
with 4% paraformaldehyde in 0.1 M cacodylate buffer (CB, pH
7.4). After further fixation of the brain at 48C overnight, 300-mm-
thick hippocampal slices were made. After incubation with block-
ing solution (5% normal goat serum in 0.1 M CB) for 1 h at room
temperature, the slices were incubated with primary anti-tau anti-
body, JM (rabbit, 1 : 300), at 48C for 2 days, followed bya secondary
anti-rabbit IgG conjugatedwith FITC-gold (goat, Nanoprobes,NY,
USA, 1 : 100) overnight. The slices were re-fixed with a mixture of
2.5% glutaraldehyde and 1% tannic acid at 48Covernight. The gold
signal enhancement procedure was performed according to
the manufacturer’s instruction (GoldEnhance-EM, Nanoprobes).
After the osmication of slices (1% OsO4–1.5% potassium
ferrocyanide in 0.1 M CB) at 48C for 10 min, the slices were
dehydrated, and embedded in epoxy resin. The stratum radiatum
of CA1 region was examined electron microscopically (JEM-
1200EX, JEOL, Japan) after metal-staining using uranium acetate
and lead citrate.
( f ) Subcellular fractionation
Partial subcellular fractionation was performed on mouse hippo-
campus basically according to a previous report [39]. Postnuclear
supernatant was subjected to centrifugation (12 500g), and divided
into the crude synaptosomal fraction and synaptosome-depleted
fraction. The crude synaptosomal fraction was further purified
by hypotonic lysis and centrifugation (25 000g), and the resul-
tant pellet was the PSD-95-rich synaptosome fraction (LP1). The
synaptosome-depleted fraction was further subjected to ultracen-
trifugation (100 000g), and separated to the microsome fraction
(P3) and cytoplasm fraction (S3). We used the following antibodies
for experiments: NeuN, mouse monoclonal (Millipore; 1 : 1000)
Tau-5, mouse monoclonal (Invitrogen; 1 : 500); PSD-95 (Millipore;
1 : 1000) and MAP2 (Millipore; 1 : 1000).
(g) Low-frequency stimulation, microdissection and
western blotting
Rat hippocampal slices fromP24 toP28were subjected to a standard
1 Hz, 900 pulses, LFS protocol (stimulation set at a predetermined
intensity; 70%of themaximal fEPSPamplitudevoltage stimulation),
using a bipolar stimulation electrode, in the presence or absence of
CT-99021 (1 mM). The dendritic CA1 region was then immediately
dissected and snap frozen. Samples were lysed and SDS–PAGE
was performed as previously shown [19]. PHF1 monoclonal anti-
body (kindly provided by Dr Peter Davies) was used at 1 : 1000
for western blot. Optical densities of immunoreactive bands were
quantified using NIH IMAGEJ software (downloaded from http://
rsb.info.nih.gov/ij/). n indicates the number of independent
experiments from different animals.
Acknowledgements. We thank Drs P. St. George-Hyslop (University of
Cambridge), EckhardMandelkow (GermanCenter for Neurodegenera-
tive Disease), M. Vitek (Duke University), O. Almeida (Max Planck
Institute of Psychiatry), N. Sausa (University of Minho) and Hana
Dawson (Duke University) for critical discussion.
rstb.royalsociet
7
 on February 5, 2014rstb.royalsocietypublishing.orgDownloaded from Funding statement. A.T. was supported by the research funding for
longevity sciences (23–39) from National Center for Geriatrics and Ger-
ontology, and the Strategic Research Programme for Brain Science
(‘Integrated Research on Neuropsychiatric Disorders’) and Grant in
Aid for Scientific Research on Innovative Areas (‘Brain Environment’)
from the Ministry of Education, Science, Sports and Culture of Japan.
K.C., D.J.W. and G.L.C. were supported by UK Wellcome Trust–MRCNeurodegenerative Disease Initiative Programme. K.C. was supported
by the Korea–UK Alzheimer’s Disease Research Consortium pro-
gramme from the Ministry of Health and Welfare (Korea). G.L.C. was
supported by the WCU Programme (Korea). I.S. was supported by the
British Council. The collaboration between K.C. andA.T. was supported
byaSasakawaFoundationgrant awarded toK.C.K.C.was supportedby
the Wolfson Research Merit Award and the Royal Society, London.ypublishing.oReferences rg
Phil.Trans.R.Soc.B
369:201301441. Andreadis A, Brown WM, Kosik KS. 1992 Structure
and novel exons of the human tau gene.
Biochemistry 31, 10 626–10 633. (doi:10.1021/
bi00158a027)
2. Goedert M, Wischik CM, Crowther RA, Walker JE,
Klug A. 1988 Cloning and sequencing of the cDNA
encoding a core protein of the paired helical
filament of Alzheimer disease: identification as the
microtubule-associated protein tau. Proc. Natl
Acad. Sci. USA 85, 4051–4055. (doi:10.1073/pnas.
85.11.4051)
3. Lindwall G, Cole RD. 1984 Phosphorylation
affects the ability of tau protein to promote
microtubule assembly. J. Biol. Chem. 259,
5301–5305.
4. Biernat J, Gustke N, Drewes G, Mandelkow EM,
Mandelkow E. 1993 Phosphorylation of Ser262
strongly reduces binding of tau to microtubules:
distinction between PHF-like immunoreactivity
and microtubule binding. Neuron 11, 153–163.
(doi:10.1016/0896-6273(93)90279-Z)
5. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW.
1975 A protein factor essential for microtubule
assembly. Proc. Natl Acad. Sci. USA 72, 1858–1862.
(doi:10.1073/pnas.72.5.1858)
6. Drubin DG, Feinstein SC, Shooter EM, Kirschner MW.
1985 Nerve growth factor-induced neurite
outgrowth in PC12 cells involves the coordinate
induction of microtubule assembly and assembly-
promoting factors. J. Cell Biol. 101, 1799–1807.
(doi:10.1083/jcb.101.5.1799)
7. Caceres A, Kosik KS. 1990 Inhibition of neurite
polarity by tau antisense oligonucleotides in
primary cerebellar neurons. Nature 343, 461–463.
(doi:10.1038/343461a0)
8. Kowall NW, Kosik KS. 1987 Axonal disruption
and aberrant localization of tau protein characterize
the neuropil pathology of Alzheimer’s disease.
Ann. Neurol. 22, 639–643. (doi:10.1002/ana.
410220514)
9. Sydow A et al. 2011 Tau-induced defects in synaptic
plasticity, learning, and memory are reversible in
transgenic mice after switching off the toxic Tau
mutant. J. Neurosci. 31, 2511–2525. (doi:10.1523/
JNEUROSCI.5245-10.2011)
10. Kimura T et al. 2010 Aggregation of detergent-
insoluble tau is involved in neuronal loss but not in
synaptic loss. J. Biol. Chem. 285, 38 692–38 699.
(doi:10.1074/jbc.M110.136630)
11. Kimura T et al. 2007 Hyperphosphorylated tau in
parahippocampal cortex impairs place learning
in aged mice expressing wild-type human tau.EMBO J. 26, 5143–5152. (doi:10.1038/sj.emboj.
7601917)
12. Bliss TV, Collingridge GL. 1993 A synaptic model of
memory: long-term potentiation in the
hippocampus. Nature 361, 31–39. (doi:10.1038/
361031a0)
13. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R,
Wolfe MS, Rowan MJ, Selkoe DJ. 2002 Naturally
secreted oligomers of amyloid b protein potently
inhibit hippocampal long-term potentiation in vivo.
Nature 416, 535–539. (doi:10.1038/416535a)
14. Collingridge GL, Peineau S, Howland JG, Wang YT.
2010 Long-term depression in the CNS. Nat. Rev.
Neurosci. 11, 459–473. (doi:10.1038/nrn2867)
15. Lovestone S et al. 1994 Alzheimer’s disease-like
phosphorylation of the microtubule-associated
protein tau by glycogen synthase kinase-3 in
transfected mammalian cells. Curr. Biol. 4,
1077–1086. (doi:10.1016/S0960-9822(00)00246-3)
16. Li Z, Jo J, Jia JM, Lo SC, Whitcomb DJ, Jiao S, Cho K,
Sheng M. 2010 Caspase-3 activation via
mitochondria is required for long-term depression
and AMPA receptor internalization. Cell 141,
859–871. (doi:10.1016/j.cell.2010.03.053)
17. Peineau S et al. 2007 LTP inhibits LTD in the
hippocampus via regulation of GSK3b. Neuron 53,
703–717. (doi:10.1016/j.neuron.2007.01.029)
18. Takashima A, Honda T, Yasutake K, Michel G,
Murayama O, Murayama M, Ishiguro K, Yamaguchi H.
1998 Activation of tau protein kinase I/glycogen
synthase kinase-3b by amyloid b peptide (25–35)
enhances phosphorylation of tau in hippocampal
neurons. Neurosci. Res. 31, 317–323. (doi:10.1016/
S0168-0102(98)00061-3)
19. Jo J, Whitcomb DJ. 2011 Ab(1–42) inhibition of
LTP is mediated by a signaling pathway involving
caspase-3, Akt1 and GSK-3b. Nat. Neurosci. 14,
545–547. (doi:10.1038/nn.2785)
20. Shipton OA et al. 2011 Tau protein is required for
amyloid b-induced impairment of hippocampal
long-term potentiation. J. Neurosci. 31, 1688–
1692. (doi:10.1523/JNEUROSCI.2610-10.2011)
21. Cho JH, Johnson GVW. 2003 Glycogen synthase
kinase 3b phosphorylates tau at both primed and
unprimed sites. Differential impact on microtubule
binding. J. Biol. Chem. 278, 187–193.
(doi:10.1074/jbc.M206236200)
22. Otvos Jr L, Feiner L, Lang E, Szendrei GI, Goedert M,
Lee VM. 1994 Monoclonal antibody PHF-1
recognizes tau protein phosphorylated at serine
residues 396 and 404. J. Neurosci. Res. 39,
669–673. (doi:10.1002/jnr.490390607)23. LoPresti P, Szuchet S, Papasozomenos SC, Zinkowski RP,
Binder LI. 1995 Functional implications for the
microtubule-associated protein tau: localization in
oligodendrocytes. Proc. Natl Acad. Sci. USA 92,
10 369–10 373. (doi:10.1073/pnas.92.22.10369)
24. Lee VM, Goedert M, Trojanowski JQ. 2001
Neurodegenerative tauopathies. Annu. Rev.
Neurosci. 24, 1121–1159. (doi:10.1146/annurev.
neuro.24.1.1121)
25. Takashima A. 2010 Tau aggregation is a therapeutic
target for Alzheimer’s disease. Curr. Alzheimer
Res. 7, 665–669. (doi:10.2174/15672051079
3611600)
26. Hoover BR et al. 2010 Tau mislocalization to
dendritic spines mediates synaptic dysfunction
independently of neurodegeneration. Neuron 68,
1067–1081. (doi:10.1016/j.neuron.2010.11.030)
27. Ittner LM et al. 2010 Dendritic function of tau
mediates amyloid-b toxicity in Alzheimer’s disease
mouse models. Cell 142, 387–397. (doi:10.1016/j.
cell.2010.06.036)
28. Zempel H, Thies E, Mandelkow E, Mandelkow EM.
2010 Ab oligomers cause localized Ca2þ elevation,
missorting of endogenous Tau into dendrites, Tau
phosphorylation, and destruction of microtubules
and spines. J. Neurosci. 30, 11 938–11 950. (doi:10.
1523/jneurosci.2357-10.2010)
29. Ittner LM, Gotz J. 2011 Amyloid-b and tau: a toxic
pas de deux in Alzheimer’s disease. Nat. Rev.
Neurosci. 12, 65–72. (doi:10.1038/nrn2967)
30. Morris M, Maeda S, Vossel K, Mucke L. 2011
The many faces of tau. Neuron 70, 410–426.
(doi:10.1016/j.neuron.2011.04.009)
31. Mondragon-Rodriguez S, Trillaud-Doppia E, Dudilot
A, Bourgeois C, Lauzon M, Leclerc N, Boehm J. 2012
Interaction of endogenous tau protein with synaptic
proteins is regulated by N-methyl-D-aspartate
receptor-dependent tau phosphorylation. J. Biol.
Chem. 287, 32 040–32 053. (doi:10.1074/jbc.
M112.401240)
32. Lasagna-Reeves CA et al. 2012 Alzheimer brain-
derived tau oligomers propagate pathology from
endogenous tau. Sci. Rep. 2, 700. (doi:10.1038/
srep00700)
33. Hoogenraad CC, Akhmanova A. 2010 Dendritic spine
plasticity: new regulatory roles of dynamic
microtubules. Neuroscientist 16, 650–661.
(doi:10.1177/1073858410386357)
34. Bue´e L, Bussie`re T, Bue´e-Scherrer V, Delacourte A,
Hof PR. 2000 Tau protein isoforms, phosphorylation
and role in neurodegenerative disorders. Brain Res.
Brain Res. Rev. 33, 95–130.
rstb.royalsocietypublishing
8
 on February 5, 2014rstb.royalsocietypublishing.orgDownloaded from 35. Lee G, Neve RL, Kosik KS. 1989 The
microtubule binding domain of tau protein.
Neuron 2, 1615–1624. (doi:10.1016/0896-
6273(89)90050-0)
36. Brandt R, Leger J, Lee G. 1995 Interaction of
tau with the neural plasma membrane mediated
by tau’s amino-terminal projection domain.
J. Cell Biol. 131, 1327–1340. (doi:10.1083/jcb.131.
5.1327)37. Hanger DP, Hughes K, Woodgett JR, Brion JP,
Anderton BH. 1992 Glycogen synthase kinase-3
induces Alzheimer’s disease-like phosphorylation of
tau: generation of paired helical filament epitopes
and neuronal localisation of the kinase. Neurosci.
Lett. 147, 58–62. (doi:10.1016/0304-3940(92)
90774-2)
38. Liu SJ et al. 2004 Tau becomes a more favorable
substrate for GSK-3 when it is prephosphorylatedby PKA in rat brain. J. Biol. Chem. 279, 50 078–50
088. (doi:10.1074/jbc.M406109200)
39. Huttner WB, Schiebler W, Greengard P,
De Camilli P. 1983 Synapsin I ( protein I), a
nerve terminal-specific phosphoprotein. III.
Its association with synaptic vesicles studied
in a highly purified synaptic vesicle preparation.
J. Cell Biol. 96, 1374–1388. (doi:10.1083/
jcb.96.5.1374).org
Phil.Trans.R.Soc.B
369:20130144
